Resources

State Plan Sponsors

State and Federal Government Agencies (collectively, Plan Sponsors) must negotiate a transparent pharmacy benefit management agreement (“PBM Agreement”) with…

Download State Plan Sponsors PDF

Related Services

Topics

Life Sciences & Pharmacy

Articles

08/18/2026

Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook

Articles

08/17/2026

Arkansas Suspends Enforcement of Act 630: What the Limited Distribution Network Ruling Means for Pharmacies

News

08/14/2026

Edgar Asebey Featured in The Capitol Forum: “A Closer Look at FDA’s Next Steps Following Advisory Committee’s Recommendation to Legalize Compounding for Wellness Peptides”

Articles

08/13/2026

Pharmacy-to-Pharmacy Inventory Transfers: Navigating PBM Audit Scrutiny Under the DSCSA

Articles

08/13/2026

FTC’s Caremark Settlement: What It Means for Pharmacies, PSAOs, and Wholesalers

Articles

08/11/2026

Cut Off Without Warning: What to Do When Mallinckrodt Restricts Your Pharmacy’s Controlled Substance Purchases

Webinars

08/20/2026

The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models

Articles

08/06/2026

What Is a State Board of Pharmacy and Why Does It Inspect You?

Articles

08/05/2026

Florida Attorney General Issues Civil Investigative Demand to CVS Health and Caremark Over Alleged Anticompetitive Practices

Articles

08/04/2026

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 2: Strategic Implications and Compliance Roadmap

News

08/03/2026

Jesse Dresser Featured in NPR: “What would it take to get peptides on the shelf?”

News

07/31/2026

Edgar Asebey Featured in CNN Health: “FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next”

News

07/31/2026

Edgar Asebey Quoted in Mezha: “FDA panel backs compounding access for six peptides, approval still pending”

News

07/30/2026

Jesse Dresser and Edgar Asebey Quoted in Peptides Business Wire: “Is legal access to peptides inevitable?”

News

07/28/2026

Edgar Asebey Quoted in WP Intelligence Health Brief: “What’s next for the peptide industry after advisory committee recommendations”

Articles

07/28/2026

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 1: PBM Transparency and New Compensation Rules

Articles

07/27/2026

Pharmacy Alert: Controlled Substance Dispensing Under Federal Scrutiny – What Pharmacies and Pharmacists Need to Know

News

07/24/2026

Jesse Dresser and Edgar Asebey Featured in Specialty Pharmacy Continuum: “Compounding Panel Backs Peptides for the 503A Bulks List, Against FDA Reviewers’ Recommendations”

Articles

07/24/2026

Illinois PBM Reforms: Audit Rights, Spread Pricing Prohibition, Rebate Pass-Through Mandate, and Enforcement Tools for Covered Entities and Plan Sponsors

News

07/23/2026

Jesse Dresser Featured in The American Journal of Managed Care: “FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week”

Call Us Now

State Plan Sponsors

Related Insights

Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook

Arkansas Suspends Enforcement of Act 630: What the Limited Distribution Network Ruling Means for Pharmacies

Edgar Asebey Featured in The Capitol Forum: “A Closer Look at FDA’s Next Steps Following Advisory Committee’s Recommendation to Legalize Compounding for Wellness Peptides”

Pharmacy-to-Pharmacy Inventory Transfers: Navigating PBM Audit Scrutiny Under the DSCSA

FTC’s Caremark Settlement: What It Means for Pharmacies, PSAOs, and Wholesalers

Cut Off Without Warning: What to Do When Mallinckrodt Restricts Your Pharmacy’s Controlled Substance Purchases

The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models

What Is a State Board of Pharmacy and Why Does It Inspect You?

Florida Attorney General Issues Civil Investigative Demand to CVS Health and Caremark Over Alleged Anticompetitive Practices

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 2: Strategic Implications and Compliance Roadmap

Jesse Dresser Featured in NPR: “What would it take to get peptides on the shelf?”

Edgar Asebey Featured in CNN Health: “FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next”

Edgar Asebey Quoted in Mezha: “FDA panel backs compounding access for six peptides, approval still pending”

Jesse Dresser and Edgar Asebey Quoted in Peptides Business Wire: “Is legal access to peptides inevitable?”

Edgar Asebey Quoted in WP Intelligence Health Brief: “What’s next for the peptide industry after advisory committee recommendations”

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 1: PBM Transparency and New Compensation Rules

Pharmacy Alert: Controlled Substance Dispensing Under Federal Scrutiny – What Pharmacies and Pharmacists Need to Know

Jesse Dresser and Edgar Asebey Featured in Specialty Pharmacy Continuum: “Compounding Panel Backs Peptides for the 503A Bulks List, Against FDA Reviewers’ Recommendations”

Illinois PBM Reforms: Audit Rights, Spread Pricing Prohibition, Rebate Pass-Through Mandate, and Enforcement Tools for Covered Entities and Plan Sponsors

Jesse Dresser Featured in The American Journal of Managed Care: “FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week”